Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD).

Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD). - Two weeks rabeprazole for ESD ulcers.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000688

Enrollment

Registered

2007-04-23

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer or gastric adenoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. gastric adenoma or early gastric carcinoma diagnosed as clinical stage IA. 2. 20 years or older who provided written informed consent. 3. Performance status ECOG 0, 1, 2. 4. Patients who could attend our hospital for 2 months after ESD.

Exclusion criteria

Exclusion criteria: 1. Patients whose lesions were diagnosed as: depth more than sm2, resected margin positive of tumor, lesions with ulcer, tumor with diffuse type cancer. 2. Patients who required surgical intervention after ESD. 3. Patients with 2 or more lesions. 4. Patients who are allergic to PPI. 5. Patients with serious comorbid diseases. 6. Patients taking NSAIDs, steroid, anticoagulants and antiplatelets. 7. Patients who were judged inappropriate by their physicians.

Design outcomes

Primary

Measure	Time frame
The rate of ulcers in scarring stage at 8 weeks after ESD.	—

Secondary

Measure	Time frame
Incidence of post-operative bleeding and abdominal symptoms.	—

Countries

Japan

Outcome results